A EFICÁCIA DA LISDEXANFETAMINA NO TRATAMENTO DO TRANSTORNO COMPULSIVO ALIMENTAR PERIÓDICO
A EFICÁCIA DA LISDEXANFETAMINA NO TRATAMENTO DO TRANSTORNO COMPULSIVO ALIMENTAR PERIÓDICO
Abstract
O Transtorno Compulsivo Alimentar Periódico é o transtorno alimentar que mais acomete indivíduos ao redor do mundo e está correlacionado a obesidade, sobrepeso e aumenta as chances de desenvolver disfunções metabólicas como a diabetes, além de também estar correlacionado a uma maior propensão de distúrbios psicopatológicos. O tratamento para o transtorno compulsivo alimentar periódico tem como objetivos obter resultados nos âmbitos comportamentais, físico e psicológico. Além das psicoterapias, como a Terapia Cognitivo Comportamental, tratamentos farmacológicos têm sido estudados em relação a eficácia no tratamento do transtorno, sendo os anti-epiléticos, antidepressivos, psicoestimulantes e medicamentos anti-obesidade, os mais estudados. A lisdexanfetamina é um psicoestimulante comumente utilizado no tratamento do TDAH (Transtorno de Déficit de Atenção e Hiperatividade) e apresenta excelentes resultados no tratamento do Transtorno Compulsivo Alimentar Periódico. O artigo vai abordar a ação da lisdexanfetamina no tratamento do Transtorno Compulsivo Alimentar Periódico e a justificativa do tema se dá pela importância e relevância nas áreas científicas e de saúde pública, uma vez que o Transtorno Compulsivo Alimentar pode levar a casos de obesidade, que é uma das doenças que mais matam no mundo.
Downloads
References
Bello NT, Yeomans BL. Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opin Drug Saf. 2018 Jan;17(1):17-23. doi: 10.1080/14740338.2018.1395854. Epub 2017 Oct 31. PMID: 29053927; PMCID: PMC6095708. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095708/
Brownley KA, Berkman ND, Peat CM, Lohr KN, Cullen KE, Bann CM, Bulik CM. Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis. Ann Intern Med. 2016 Sep 20;165(6):409-20. doi: 10.7326/M15-2455. Epub 2016 Jun 28. PMID: 27367316; PMCID: PMC5637727. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5637727/
Davis LE, Attia E. Recent advances in therapies for eating disorders. F1000Res. 2019 Sep 26;8:F1000 Faculty Rev-1693. doi: 10.12688/f1000research.19847.1. PMID: 31598212; PMCID: PMC6764116.Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764116/
Griffiths KR, Aparício L, Braund TA, Yang J, Harvie G, Harris A, Hay PJ, Touyz S, Kohn MR. Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder. Front Psychol. 2021 Aug 31;12:716010. doi: 10.3389/fpsyg.2021.716010. PMID: 34531798; PMCID: PMC8439192. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439192/
Guerdjikova AI, Mori N, Casuto LS, McElroy SL. Novel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamine. Neuropsychiatr Dis Treat. 2016 Apr 18;12:833-41. doi: 10.2147/NDT.S80881. PMID: 27143885; PMCID: PMC4841437. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841437/
Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Sep 1;74(9):903-910. doi: 10.1001/jamapsychiatry.2017.1889. PMID: 28700805; PMCID: PMC5710231. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710231/
Klein DA, Sylvester JE, Schvey NA. Eating Disorders in Primary Care: Diagnosis and Management. Am Fam Physician. 2021 Jan 1;103(1):22-32. Erratum in: Am Fam Physician. 2021 Mar 1;103(5):263. PMID: 33382560. Disponível em: https://www.aafp.org/pubs/afp/issues/2021/0101/p22.html
- McCuen-Wurst C, Ruggieri M, Allison KC. Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. Ann N Y Acad Sci. 2018 Jan;1411(1):96-105. doi: 10.1111/nyas.13467. Epub 2017 Oct 16. PMID: 29044551; PMCID: PMC5788730. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788730/
McElroy, Susan L. “Pharmacologic Treatments for Binge-Eating Disorder.” The Journal of Clinical Psychiatry, vol. 78, no. Suppl 1, 25 Jan. 2017, pp. 14–19, https://doi.org/10.4088/jcp.sh16003su1c.03. Disponível em: https://www.psychiatrist.com/jcp/eating/pharmacologic-treatments-binge-eating-disorder/
McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology. 2016 Apr;41(5):1251-60. doi: 10.1038/npp.2015.275. Epub 2015 Sep 9. PMID: 26346638; PMCID: PMC4793109. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793109/
Reas DL, Grilo CM. Pharmacological treatment of binge eating disorder: update review and synthesis. Expert Opin Pharmacother. 2015;16(10):1463-78. doi: 10.1517/14656566.2015.1053465. Epub 2015 Jun 4. PMID: 26044518; PMCID: PMC4491373. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491373/
Shire Farmacêutica Brasil LTDA. Venvanse (dimesilato de lisdexanfetamina). Disponível em: https://io.convertiez.com.br/m/drogal/uploads/bulas/7898924769065/bula-venvanse-paciente.pdf
SILVA, Laís Véras Spillere. Farmacoterapia do Transtorno do Déficit de Atenção. 2020. Pag. 28,29,30,31. Disponível em: https://repositorio.ufsc.br/bitstream/handle/123456789/218567/LAIS-TCC-UFSC-2020-11-30%20%285%29-convertido%20%285%29.pdf?sequence=1&isAllowed=y
- Svedlund NE, Norring C, Ginsberg Y, von Hausswolff-Juhlin Y. Behandling av ätstörningar vid samtidiga ADHD-symtom - Observerat samband kan ge nya möjligheter till medicinering, främst av bulimia nervosa – men ännu finns kunskapsluckor [Treatment of eating disorders with concurrent ADHD symptoms: knowledge, knowledge gaps and clinical implications]. Lakartidningen. 2019 Sep 17;116:FMUT. Swedish. PMID: 31529419. Disponível em: https://lakartidningen.se/klinik-och-vetenskap-1/artiklar-1/klinisk-oversikt/2019/09/behandling-av-atstorningar-vid-samtidiga-adhd-symtom/
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Revista Multidisciplinar do Nordeste Mineiro
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
